![N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly](/upload/1124/V44276.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
FAPGG targets angiotensin-converting enzyme (ACE), which is a key enzyme in the renin-angiotensin system that converts angiotensin I to the potent vasoconstrictor angiotensin II. As a substrate for ACE, FAPGG is not an inhibitor but is cleaved by the enzyme. The compound's utility lies in its ability to serve as a reporter for ACE activity, which is important in the study of hypertension and other cardiovascular diseases.
|
|---|---|
| ln Vitro |
In vitro, FAPGG is used as a chromogenic substrate in a continuous spectrophotometric assay for ACE. The assay measures the decrease in absorbance at 340 nm as the substrate is cleaved by ACE. The rate of cleavage is proportional to enzyme activity. This allows for the sensitive and rapid determination of ACE activity in biological samples.
|
| ln Vivo |
In vivo applications of FAPGG are not typical, as it is primarily a research reagent for in vitro enzyme assays. It is not administered to living organisms for therapeutic purposes. Its use is confined to laboratory settings for measuring ACE activity in biological fluids.
|
| Enzyme Assay |
A cell-free assay for FAPGG involves incubating the substrate with a sample containing ACE and monitoring the decrease in absorbance at 340 nm over time. The reaction is typically carried out in a buffer at a specific pH and temperature. The initial rate of absorbance change is calculated and used to determine ACE activity. This is a standard method for measuring ACE activity in serum, plasma, and other biological fluids.
|
| Cell Assay |
Cellular experiments with FAPGG are not typical, as it is used as a biochemical reagent in cell-free enzyme assays rather than in cell-based studies.
|
| Animal Protocol |
In vivo animal experiments are not applicable for FAPGG as it is a chromogenic substrate used in vitro.
|
| ADME/Pharmacokinetics |
FAPGG has a molecular formula of C20H21N3O6 and a molecular weight of 399.40 g/mol. It is a solid. Specific pharmacokinetic properties are not applicable as it is not a therapeutic drug. It is used in vitro as a research reagent. For storage, it should be kept at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity data for FAPGG are not provided in the available sources. As a peptide substrate, it is generally considered to have low toxicity for its intended research applications. It is intended for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly (CAS: 64967-39-1) is a chromogenic substrate for angiotensin-converting enzyme (ACE). Its synonyms include FAPGG and FA-Phe-Gly-Gly-OH. It is used for the continuous spectrophotometric determination of ACE activity, which is important in the study of hypertension and related cardiovascular conditions.
|
| Molecular Formula |
C20H21N3O6
|
|---|---|
| Molecular Weight |
399.3972
|
| Exact Mass |
399.143
|
| CAS # |
64967-39-1
|
| PubChem CID |
6438387
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
842.3±65.0 °C at 760 mmHg
|
| Melting Point |
245ºC (dec.)(lit.)
|
| Flash Point |
463.2±34.3 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.603
|
| LogP |
1.77
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
29
|
| Complexity |
615
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)/C=C/C2=CC=CO2
|
| InChi Key |
ZDLZKMDMBBMJLI-FDMDGMSGSA-N
|
| InChi Code |
InChI=1S/C20H21N3O6/c24-17(9-8-15-7-4-10-29-15)23-16(11-14-5-2-1-3-6-14)20(28)22-12-18(25)21-13-19(26)27/h1-10,16H,11-13H2,(H,21,25)(H,22,28)(H,23,24)(H,26,27)/b9-8+/t16-/m0/s1
|
| Chemical Name |
2-[[2-[[(2S)-2-[[(E)-3-(furan-2-yl)prop-2-enoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~250.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5038 mL | 12.5188 mL | 25.0376 mL | |
| 5 mM | 0.5008 mL | 2.5038 mL | 5.0075 mL | |
| 10 mM | 0.2504 mL | 1.2519 mL | 2.5038 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
